BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 30428345)

  • 1. TP63-Mediated Enhancer Reprogramming Drives the Squamous Subtype of Pancreatic Ductal Adenocarcinoma.
    Somerville TDD; Xu Y; Miyabayashi K; Tiriac H; Cleary CR; Maia-Silva D; Milazzo JP; Tuveson DA; Vakoc CR
    Cell Rep; 2018 Nov; 25(7):1741-1755.e7. PubMed ID: 30428345
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Super-Enhancer-Driven Long Non-Coding RNA LINC01503, Regulated by TP63, Is Over-Expressed and Oncogenic in Squamous Cell Carcinoma.
    Xie JJ; Jiang YY; Jiang Y; Li CQ; Lim MC; An O; Mayakonda A; Ding LW; Long L; Sun C; Lin LH; Chen L; Wu JY; Wu ZY; Cao Q; Fang WK; Yang W; Soukiasian H; Meltzer SJ; Yang H; Fullwood M; Xu LY; Li EM; Lin DC; Koeffler HP
    Gastroenterology; 2018 Jun; 154(8):2137-2151.e1. PubMed ID: 29454790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Co-activation of super-enhancer-driven CCAT1 by TP63 and SOX2 promotes squamous cancer progression.
    Jiang Y; Jiang YY; Xie JJ; Mayakonda A; Hazawa M; Chen L; Xiao JF; Li CQ; Huang ML; Ding LW; Sun QY; Xu L; Kanojia D; Jeitany M; Deng JW; Liao LD; Soukiasian HJ; Berman BP; Hao JJ; Xu LY; Li EM; Wang MR; Bi XG; Lin DC; Koeffler HP
    Nat Commun; 2018 Sep; 9(1):3619. PubMed ID: 30190462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP63 links chromatin remodeling and enhancer reprogramming to epidermal differentiation and squamous cell carcinoma development.
    Yi M; Tan Y; Wang L; Cai J; Li X; Zeng Z; Xiong W; Li G; Li X; Tan P; Xiang B
    Cell Mol Life Sci; 2020 Nov; 77(21):4325-4346. PubMed ID: 32447427
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancer Reprogramming Promotes Pancreatic Cancer Metastasis.
    Roe JS; Hwang CI; Somerville TDD; Milazzo JP; Lee EJ; Da Silva B; Maiorino L; Tiriac H; Young CM; Miyabayashi K; Filippini D; Creighton B; Burkhart RA; Buscaglia JM; Kim EJ; Grem JL; Lazenby AJ; Grunkemeyer JA; Hollingsworth MA; Grandgenett PM; Egeblad M; Park Y; Tuveson DA; Vakoc CR
    Cell; 2017 Aug; 170(5):875-888.e20. PubMed ID: 28757253
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma.
    Hegde GV; de la Cruz C; Giltnane JM; Crocker L; Venkatanarayan A; Schaefer G; Dunlap D; Hoeck JD; Piskol R; Gnad F; Modrusan Z; de Sauvage FJ; Siebel CW; Jackson EL
    Elife; 2019 May; 8():. PubMed ID: 31144617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TP63, SOX2, and KLF5 Establish a Core Regulatory Circuitry That Controls Epigenetic and Transcription Patterns in Esophageal Squamous Cell Carcinoma Cell Lines.
    Jiang YY; Jiang Y; Li CQ; Zhang Y; Dakle P; Kaur H; Deng JW; Lin RY; Han L; Xie JJ; Yan Y; Doan N; Zheng Y; Mayakonda A; Hazawa M; Xu L; Li Y; Aswad L; Jeitany M; Kanojia D; Guan XY; Said JW; Yang W; Fullwood MJ; Lin DC; Koeffler HP
    Gastroenterology; 2020 Oct; 159(4):1311-1327.e19. PubMed ID: 32619460
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interplay between ΔNp63 and miR-138-5p regulates growth, metastasis and stemness of oral squamous cell carcinoma.
    Zhuang Z; Xie N; Hu J; Yu P; Wang C; Hu X; Han X; Hou J; Huang H; Liu X
    Oncotarget; 2017 Mar; 8(13):21954-21973. PubMed ID: 28423539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZBED2 is an antagonist of interferon regulatory factor 1 and modifies cell identity in pancreatic cancer.
    Somerville TDD; Xu Y; Wu XS; Maia-Silva D; Hur SK; de Almeida LMN; Preall JB; Koo PK; Vakoc CR
    Proc Natl Acad Sci U S A; 2020 May; 117(21):11471-11482. PubMed ID: 32385160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DeltaNp63-dependent super enhancers define molecular identity in pancreatic cancer by an interconnected transcription factor network.
    Hamdan FH; Johnsen SA
    Proc Natl Acad Sci U S A; 2018 Dec; 115(52):E12343-E12352. PubMed ID: 30541891
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MiR-301a transcriptionally activated by HIF-2α promotes hypoxia-induced epithelial-mesenchymal transition by targeting TP63 in pancreatic cancer.
    Zhang KD; Hu B; Cen G; Yang YH; Chen WW; Guo ZY; Wang XF; Zhao Q; Qiu ZJ
    World J Gastroenterol; 2020 May; 26(19):2349-2373. PubMed ID: 32476798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional control of autophagy-lysosome function drives pancreatic cancer metabolism.
    Perera RM; Stoykova S; Nicolay BN; Ross KN; Fitamant J; Boukhali M; Lengrand J; Deshpande V; Selig MK; Ferrone CR; Settleman J; Stephanopoulos G; Dyson NJ; Zoncu R; Ramaswamy S; Haas W; Bardeesy N
    Nature; 2015 Aug; 524(7565):361-5. PubMed ID: 26168401
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TNF-α modulates genome-wide redistribution of ΔNp63α/TAp73 and NF-κB cREL interactive binding on TP53 and AP-1 motifs to promote an oncogenic gene program in squamous cancer.
    Si H; Lu H; Yang X; Mattox A; Jang M; Bian Y; Sano E; Viadiu H; Yan B; Yau C; Ng S; Lee SK; Romano RA; Davis S; Walker RL; Xiao W; Sun H; Wei L; Sinha S; Benz CC; Stuart JM; Meltzer PS; Van Waes C; Chen Z
    Oncogene; 2016 Nov; 35(44):5781-5794. PubMed ID: 27132513
    [TBL] [Abstract][Full Text] [Related]  

  • 14. ΔNp63 activates the Fanconi anemia DNA repair pathway and limits the efficacy of cisplatin treatment in squamous cell carcinoma.
    Bretz AC; Gittler MP; Charles JP; Gremke N; Eckhardt I; Mernberger M; Mandic R; Thomale J; Nist A; Wanzel M; Stiewe T
    Nucleic Acids Res; 2016 Apr; 44(7):3204-18. PubMed ID: 26819410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Epigenomic Profiling Discovers Trans-lineage SOX2 Partnerships Driving Tumor Heterogeneity in Lung Squamous Cell Carcinoma.
    Sato T; Yoo S; Kong R; Sinha A; Chandramani-Shivalingappa P; Patel A; Fridrikh M; Nagano O; Masuko T; Beasley MB; Powell CA; Zhu J; Watanabe H
    Cancer Res; 2019 Dec; 79(24):6084-6100. PubMed ID: 31551362
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A TEAD2-Driven Endothelial-Like Program Shapes Basal-Like Differentiation and Metastasis of Pancreatic Cancer.
    Yoo HB; Moon JW; Kim HR; Lee HS; Miyabayashi K; Park CH; Ge S; Zhang A; Tae YK; Sub Y; Park HW; Gee HY; Notta F; Tuveson DA; Bang S; Kim MY; Roe JS
    Gastroenterology; 2023 Jul; 165(1):133-148.e17. PubMed ID: 36907523
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identifying pathways regulating the oncogenic p53 family member ΔNp63 provides therapeutic avenues for squamous cell carcinoma.
    Pokorna Z; Vyslouzil J; Vojtesek B; Coates PJ
    Cell Mol Biol Lett; 2022 Feb; 27(1):18. PubMed ID: 35196980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ATDC mediates a TP63-regulated basal cancer invasive program.
    Palmbos PL; Wang Y; Bankhead Iii A; Kelleher AJ; Wang L; Yang H; Ahmet ML; Gumkowski ER; Welling SD; Magnuson B; Leflein J; Lorenzatti Hiles G; Abel EV; Dziubinski ML; Urs S; Day ML; Ljungman ME; Simeone DM
    Oncogene; 2019 May; 38(18):3340-3354. PubMed ID: 30643195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interplay and cooperation between SREBF1 and master transcription factors regulate lipid metabolism and tumor-promoting pathways in squamous cancer.
    Li LY; Yang Q; Jiang YY; Yang W; Jiang Y; Li X; Hazawa M; Zhou B; Huang GW; Xu XE; Gery S; Zhang Y; Ding LW; Ho AS; Zumsteg ZS; Wang MR; Fullwood MJ; Freedland SJ; Meltzer SJ; Xu LY; Li EM; Koeffler HP; Lin DC
    Nat Commun; 2021 Jul; 12(1):4362. PubMed ID: 34272396
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ΔNp63α is a super enhancer-enriched master factor controlling the basal-to-luminal differentiation transcriptional program and gene regulatory networks in nasopharyngeal carcinoma.
    Cai J; Chen S; Yi M; Tan Y; Peng Q; Ban Y; Yang J; Li X; Zeng Z; Xiong W; McCarthy JB; Li G; Li X; Xiang B
    Carcinogenesis; 2020 Sep; 41(9):1282-1293. PubMed ID: 31826234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.